Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry
The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice.
Authors
- Isabel Munévar
- Luis Antonio Salazar (ORCID: https://orcid.org/0000-0001-9515-937X)
- Juan Morales (ORCID: https://orcid.org/0000-0001-7824-0491)
- Domingo Saavedra Ramírez
- Diana Cuervo (ORCID: https://orcid.org/0009-0002-7827-5250)
- Virginia Abello Polo (ORCID: https://orcid.org/0000-0001-6507-4041)
- Claudia Agudelo (ORCID: https://orcid.org/0000-0002-3174-3208)
- Kenny Gálvez (ORCID: https://orcid.org/0000-0003-1192-9053)
- Carlos Bermúdez (ORCID: https://orcid.org/0000-0002-1226-3735)
- Olga Paola Omaña-Orduz (ORCID: https://orcid.org/0000-0002-3148-5130)
- Carla Boquimpani (ORCID: https://orcid.org/0000-0001-7396-2495)
- Guillermo Quintero (ORCID: https://orcid.org/0000-0002-3671-6911)
- William Mantilla
- Carmen Rosales Oliveros (ORCID: https://orcid.org/0000-0002-6099-3492)
- Jheremy Reyes (ORCID: https://orcid.org/0000-0002-0082-0477)
- Henry Idrobo (ORCID: https://orcid.org/0000-0002-7686-5874)
- Claudia Sossa (ORCID: https://orcid.org/0000-0001-9876-222X)
- Rigoberto Gómez Gutiérrez (ORCID: https://orcid.org/0000-0001-7242-6930)
- Jorge Daza
- Mario Correa (ORCID: https://orcid.org/0000-0003-2040-3301)
- Juan Manuel Herrera (ORCID: https://orcid.org/0000-0002-9522-6840)
- José Ramirez
- J. Serrano (ORCID: https://orcid.org/0000-0002-2699-108X)
- MA Alzate
- Carlos Varón Jaimes
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- OncoMed (United States) (US)
- Universidad de La Sabana (CO)
- Universidad de Los Andes (CO)
- Universidad Autónoma de Bucaramanga (CO)
- Hospital Universitario de San Vicente Fundación (CO)
- Francisco de Paula Santander University (CO)
- Hemorio (BR)
- Clínica Rementería (ES)
- Fundación Con Vida (CO)
- Hospital Pablo Tobon Uribe (CO)
- Foundation for Clinical and Applied Cancer Research (CO)
- Corporación Unificada Nacional de Educación Superior (CO)
- Fundación Santa Fe de Bogotá (CO)
- Foscal Hospital (CO)
- Asociación Colombiana de Gastroenterología (CO)
- Centro de Investigación de la Caña de Azúcar de Colombia (CO)
- Leukemia and Lymphoma Society (US)
- Hospital Universitario Infantil San José (CO)
- Fundación Universitaria Sanitas (CO)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1016/j.clml.2024.12.015
- Citations
- 2
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Amgen
- Bristol-Myers Squibb
- Roche
- AbbVie
- Novartis Pharmaceuticals Corporation
- Takeda Pharmaceutical Company
- BeiGene
- Astellas Pharma
- Janssen Pharmaceuticals